HIF-1 as a target for drug development
The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Sensing and responding to fluxes in oxygen tension is perhaps the single most important variable in physiology, and animal tissues have developed a number of essential mechanisms to cope with the stress of low physiological oxygen levels, or hypoxia. Among these coping mechanisms is the response mediated by the hypoxia-inducible transcription factor, or HIF-1. HIF-1 is an essential component in changing the transcriptional repertoire of tissues as oxygen levels drop, and could prove to be a very important target for drug development, as treatments evolve for diseases, such as cancer, heart disease and stroke, in which hypoxia is a central aspect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, growing evidence showed that the strong cell–cell contacts of tumor spheroids in combination with dense ECM deposition is responsible for chemoresistance by posing a physical barrier to the penetration of chemotherapeutics and immune cells similar to in vivo.[ 48 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [48]
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Most importantly, overexpression of HIF-1α or HIF-2α have been implicated as poor prognostic indicators for a variety of tumour”
BackgroundHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“Although the role of HIF-1α in human tumours remains correlative, in transplanted tumours in immunodeficient mice, loss of HIF-1α or HIF-1β results in reduced tumour growth, decreased angiogenesis and increased responsiveness to radiotherap”
BackgroundHuang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Research works printed but not linked: 1
- Flamme, I., Frolich, T. & Risau, W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. 173, 206–210 (1997). · DOI · Paper page
Cited by
Items 201–300 of 671
A microsystem for sensing and patterning oxidative microgradients during cell culture
Park, J., Bansal, T., Pinelis, M., & Maharbiz, M. M. (2006) · Lab on a Chip · doi:10.1039/b516483d · Cited by 79
YAMADA, N., YAMANEGI, K., OHYAMA, H., HATA, M., NAKASHO, K., FUTANI, H., OKAMURA, H., & TERADA, N. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1630 · Cited by 62
Singh, M., Suman, S., & Shukla, Y. (2014) · BioMed Research International · doi:10.1155/2014/243452 · Cited by 83
“Since its discovery in the early 1990s, HIF-1 has quickly attracted interest both for its involvement in fundamental biological processes, including tumormetabolism, angiogenesis, metastasis, and inflammation, and for its potential role as therapeutic target [37].”
BackgroundLerman, O. Z., Greives, M. R., Singh, S. P., Thanik, V. D., Chang, C. C., Seiser, N., Brown, D. J., Knobel, D., Schneider, R. J., Formenti, S. C., et al. (2010) · Blood · doi:10.1182/blood-2009-03-213629 · Cited by 65
Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)
Nagle, D. G., & Zhou, Y. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777698783 · Cited by 77
Indazole Derivatives: Promising Anti-tumor Agents
Wan, Y., He, S., Li, W., & Tang, Z. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666180510113822 · Cited by 67
Neuroprotective effect of peroxiredoxin 6 against hypoxia-induced retinal ganglion cell damage
Tulsawani, R., Kelly, L. S., Fatma, N., Chhunchha, B., Kubo, E., Kumar, A., & Singh, D. P. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-125 · Cited by 68
“deactivation of several transcription factors [8-10,12,43].”
BackgroundDong, L., You, S., Zhang, Q., Osuka, S., Devi, N. S., Kaluz, Š., Ferguson, J. H., Yang, H., Chen, G., Wang, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1368 · Cited by 66
“Hypoxia-inducible factor (HIF), the master transcriptional regulator of hypoxia-mediated gene responses, plays a key role in tumorigenesis and metastasis (6, 7).”
BackgroundHypoxia and HIF‐1α in Chondrogenesis
SCHIPANI, E. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.009 · Cited by 62
Kim, Y., Jang, M., Lim, S., Won, H., Yoon, K., Park, J., Kim, H. J., Kim, B., Park, W.-S., Ha, J., et al. (2011) · Hepatology · doi:10.1002/hep.24539 · Cited by 70
Tajima, N., Schönherr, K., Niedling, S., Kaatz, M., Kanno, H., Schönherr, R., & Heinemann, S. H. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2005.096818 · Cited by 61
“The identification of HIF-1α/1β as a central switch for responses to hypoxia in cancer cells makes it a very attractive candidate for pharmacological intervention and strong efforts are underway to identify appropriate compounds that interfere with HIFs (Giacca et al. 2003).”
BackgroundInfluentialMeng, L., Wang, C., Lu, Y., Sheng, G., Yang, L., Wu, Z., Xu, H., Han, C., Lu, Y., & Han, F. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c00347 · Cited by 62
Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1α inhibitors
Shimizu, K., Maruyama, M., Yasui, Y., Minegishi, H., Ban, H. S., & Nakamura, H. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.037 · Cited by 66
YC-1 Induces S Cell Cycle Arrest and Apoptosis by Activating Checkpoint Kinases
Yeo, E.-J., Ryu, J.-H., Chun, Y.-S., Cho, Y.-S., Jang, I.-J., Cho, H., Kim, J., Kim, M.-S., & Park, J.-W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4460 · Cited by 62
Spinella, F., Rosanò, L., Duca, M. D., Castro, V. D., Nicotra, M. R., Natali, P. G., & Bagnato, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011241 · Cited by 64
“mediated by two distinct heterodimeric complexes composed by a constitutively expressed HIF-b subunit bound to either HIF-1a or HIF-2a [6–9].”
RetractedBurkitt, K., Chun, S. Y., Dang, D. T., & Dang, L. H. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0944 · Cited by 61
Dai, J., Fishback, J. A., Zhou, Y., & Nagle, D. G. (2006) · Journal of Natural Products · doi:10.1021/np060278q · Cited by 62
Hypoxia: A Double-Edged Sword During Fungal Pathogenesis?
Chung, H., & Lee, Y. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01920 · Cited by 61
MITOCHONDRIAL CHOLESTEROL AND CANCER
García‐Ruiz, C., de la Rosa, L. C., Ribas, V., & Fernández-Checa, J. C. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.014 · Cited by 62
Dubey, R., Levin, M. D., Szabó, L., László, C., Kushal, S., Singh, J. B., Oh, P., Schnitzer, J. E., & Olenyuk, B. Z. (2013) · Journal of the American Chemical Society · doi:10.1021/ja400805b · Cited by 64
HIF-1α inhibitors: Synthesis and biological evaluation of novel moracin O and P analogues
Xia, Y., Jin, Y., Kaur, N., Choi, Y., & Lee, K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.03.022 · Cited by 62
Hao, J., Song, X., Song, B., Liu, Y., Wei, L., Wang, X., & Yu, J. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.4 · Cited by 65
Cancer and diet: How are they related?
Sung, B., Prasad, S., Yadav, V. R., Lavasanifar, A., & Aggarwal, B. B. (2011) · Free Radical Research · doi:10.3109/10715762.2011.582869 · Cited by 64
Contribution of hypoxia inducible factor-1 during viral infections
Reyes, A., Corrales, N., Gálvez, N. M. S., Bueno, S. M., Kalergis, A. M., & González, P. A. (2020) · Virulence · doi:10.1080/21505594.2020.1836904 · Cited by 59
“factor may help inhibit inflammatory responses [157].”
BackgroundNaik, R., Won, M., Ban, H. S., Bhattarai, D., Xu, X., Eo, Y., Hong, Y. S., Singh, S., Choi, Y., Ahn, H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501241g · Cited by 64
The “Emigration, Migration, and Immigration” of Prostate Cancer
Pienta, K. J., & Loberg, R. D. (2005) · Clinical Prostate Cancer · doi:10.3816/cgc.2005.n.008 · Cited by 58
Sixto‐López, Y., Gómez-Vidal, J. A., de Pedro, N., Bello, M., Rosales‐Hernández, M. C., & Correa‐Basurto, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-67112-4 · Cited by 60
Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics
Swenson, C., Mandava, G., Thomas, D. M., & Moellering, R. E. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00423 · Cited by 61
Mun, J.-Y., Jabbar, A. A., Devi, N. S., Yin, S., Wang, Y., Tan, C., Culver, D. G., Snyder, J. P., Meir, E. G. V., & Goodman, M. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300752n · Cited by 59
Marcus, K. J., & Haas-Kogan, D. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00008-x · Cited by 56
Parhira, S., Zhu, G., Chen, M., Bai, L., & Jiang, Z. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.10.070 · Cited by 60
“…in response to hypoxia, i.e., vascular endothelial growth factors (VEGF), glucose transporter isoform (GLUT1), hexokinase (HK-) 1 and 2, etc, (Giaccia et al., 2003; Strieter, 2005; Zhang et al., 2008; Semenza, 2012a, 2012b, 2012c) and also controls the expression of genes involved in…”
BackgroundShi, X., Sung, S. H. P., Lee, M. M. S., Kwok, R. T. K., Sung, H. H. Y., Liu, H., Lam, J. W. Y., Williams, I. D., Liu, B., & Tang, B. Z. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02848j · Cited by 58
Molecular mechanisms of the neuroprotective neurorescue action of multi-target green tea polyphenols
Mandel, S. A., Weinreb, O., Amit, T., & Youdim, M. B. H. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s286 · Cited by 60
Cai, X. F., Jin, X., Lee, D., Yang, Y. T., Lee, K., Hong, Y., Lee, J.-H., & Lee, J. J. (2006) · Journal of Natural Products · doi:10.1021/np060081y · Cited by 55
Versatile pharmacological actions of YC-1: anti-platelet to anticancer
Chun, Y., Yeo, E.-J., & Park, J. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.01.005 · Cited by 57
Huang, C., Li, Y., Li, Z., Xu, Y., Li, N., Ge, Y., Dong, J., Chang, A., Zhao, T., Wang, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3533 · Cited by 61
“HIF1 levels in tumor tissues are elevated in response to hypoxia; activation of some oncogenes, such as Ras and PI3K/Akt; and inactivation of tumor suppressors, such as VHL or PTEN (4).”
BackgroundSeo, K., Seo, S., Ki, S. H., & Shin, S. M. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.11.014 · Cited by 54
“For example, they induce angiogenesis and switch glucose metabolism to glycolysis [1,4].”
BackgroundNewcomb, E. W., Lukyanov, Y., Schnee, T., Ali, M., Li, L., & Zagzag, D. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.5.1121 · Cited by 67
Kim, H., Kasper, A. C., Moon, E. J., Park, Y., Wooten, C. M., Dewhirst, M. W., & Hong, J. (2008) · Organic Letters · doi:10.1021/ol8024617 · Cited by 53
Creighton-Gutteridge, M., Cardellina, J. H., Stephen, A. G., Rapisarda, A., Uranchimeg, B., Hite, K., Denny, W. A., Shoemaker, R. H., & Melillo, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2301 · Cited by 51
Naik, R., Ban, H. S., Jang, K., Kim, I., Xu, X., Harmalkar, D. S., Shin, S.-A., Kim, M., Kim, B., Park, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01231 · Cited by 60
Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth
Choi, J. Y., Ramasamy, T., Tran, T. H., Ku, S., Shin, B. S., Choi, H., Yong, C. S., & Kim, J. O. (2014) · Journal of Materials Chemistry B · doi:10.1039/c4tb01442a · Cited by 51
Radiation sensitization with redox modulators: A promising approach
Rosenberg, A. R., & Knox, S. J. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.10.013 · Cited by 52
Accumulation of hypoxia-inducible factor-1α is limited by transcription-dependent depletion
Demidenko, Z. N., Rapisarda, A., Garayoa, M., Giannakakou, P., Melillo, G., & Blagosklonny, M. V. (2005) · Oncogene · doi:10.1038/sj.onc.1208636 · Cited by 65
“In theory, pharmacological manipulation of HIF-1amay find clinical applications in numerous diseases, including cancer (Semenza, 2003; Giaccia et al., 2003; Rapisarda et al., 2004a).”
BackgroundLi, H., Bubley, G. J., Balk, S. P., Gaziano, J. M., Pollak, M., Stampfer, M. J., & Ma, J. (2007) · The Prostate · doi:10.1002/pros.20589 · Cited by 53
“For these reasons, HIF-1 has become an attractive target for the development of anti-cancer drugs [2,23].”
BackgroundIn Vivo Pharmacodynamic Imaging of Proteasome Inhibition
Kimbrel, E. A., Davis, T. N., Bradner, J. E., & Kung, A. L. (2009) · Molecular Imaging · doi:10.2310/7290.2009.00007 · Cited by 51
“The ability of the ODD domain to independently promote protein degradation was first biochemically described over 10 years ago,(20) yet more recent studies have described its utility for in vivo reporter assays examining oxygen deficiency, HIF activity, and tumor biology.(19,21,30) In this study, we showed that ODD al…”
BackgroundChen, H., Bi, Q., Yao, Y., & Tan, N. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb00665b · Cited by 50
Yoo, Y.-G., Christensen, J., & Huang, L. E. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2360 · Cited by 50
Okail, M. S. A. (2010) · Journal of Saudi Chemical Society · doi:10.1016/j.jscs.2010.02.005 · Cited by 57
Patel, M. B., Sachidanandan, M., & Adnan, M. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4545-5 · Cited by 55
PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer
Zhang, X., Wang, K., Feng, X., Wang, J., Chu, Y., Jia, C., He, Q., & Chen, C. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04352-w · Cited by 49
“HIF1α is induced by hypoxia and its expression is significantly upregulated after anti-angiogenic therapy, resulting in drug resistance [10].”
BackgroundThe Unfolded Protein Response and Integrated Stress Response to Anoxia
Rzymski, T., & Harris, A. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2126 · Cited by 60
Liu, X.-W., Cai, T.-Y., Zhu, H., Cao, J., Su, Y., Hu, Y.-Z., He, Q.-J., & Yang, B. (2013) · Autophagy · doi:10.4161/auto.26838 · Cited by 48
“A growing number of agents that can inhibit HIF1A activity have shown significant activity in arresting tumor xenograft growth.(14,15) Accordingly, we hypothesized that a therapeutic strategy aimed at both specifically killing hypoxic cells and inhibiting HIF1A expression may provide enhanced antitumor activity and cl…”
BackgroundĐạt, N. T., Jin, X., Hong, Y., & Lee, J. J. (2010) · Journal of Natural Products · doi:10.1021/np900820p · Cited by 49
Mitochondrial Alterations During Carcinogenesis
Wang, X., Peralta, S., & Moraes, C. T. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00004-6 · Cited by 49
Mao, Z.-J., Tang, Q., Zhang, C., Qin, Z., Pang, B., Wei, P.-K., Liu, B., & Chou, Y.-N. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13056521 · Cited by 48
“RNA interference (RNAi) or pharmacological compounds has improved the anti-tumor efficacy in murine cancer models [15].”
BackgroundTriterpenoids and diarylheptanoids from alnus hirsuta inhibit HIF-1 in ags cells
Jin, W., Cai, X. F., Na, M., Lee, J. J., & Bae, K. (2007) · Archives of Pharmacal Research · doi:10.1007/bf02980213 · Cited by 47
Jayatunga, M. K. P., Thompson, S., McKee, T. C., Chan, M. C., Reece, K. M., Hardy, A., Sekirnik, R., Seden, P. T., Cook, K. M., McMahon, J. B., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.006 · Cited by 49
Hypoxia-Inducible Factor 1 as a Possible Target for Cancer Chemoprevention
López‐Lázaro, M. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0369 · Cited by 47
“HIF-1 is considered a potential target for cancer therapy, and, recently, many efforts to develop new HIF-1-targeting agents have been made by both academic and pharmaceutical industry laboratories (13, 20, 32-34).”
BackgroundBiomaterials with cancer cell-specific cytotoxicity: challenges and perspectives
Chu, Z., Wang, W., Zheng, W., Fu, W., Wang, Y., Wang, H., & Qian, H. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00636d · Cited by 45
Role of Carcinoma-Associated Fibroblasts and Hypoxia in Tumor Progression
Giaccia, A. J., & Schipani, E. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_73 · Cited by 48
Self-citationZhong, Q., Zhou, Y., Ye, W., Cai, T., Zhang, X., & Deng, D. Y. B. (2012) · Stem Cells and Development · doi:10.1089/scd.2011.0604 · Cited by 45
“Furthermore, the central role of HIF-1 in the cellular response to hypoxia makes this factor an attractive therapeutic target for ischemic stroke [17].”
Ferns, G. A., & Heikal, L. (2016) · Angiology · doi:10.1177/0003319716662423 · Cited by 48
Mechanistic considerations in chemotherapeutic activity of caffeine
Tej, G. N. V. C., & Nayak, P. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.144 · Cited by 47
Jiang, M., Wang, B., Wang, C., He, B., Fan, H., Shao, Q., Gao, L., Liu, Y., Yan, G., & Pu, J. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.03.012 · Cited by 49
“Increases in HIF-1 activity could increase survival during hypoxia, and increase angiogenesis at sites of vascular disruption or dysfunction (Giaccia et al., 2003).”
BackgroundInduction of the Hypoxia-Inducible Factor System by Low Levels of Heat Shock Protein 90 Inhibitors
Ibrahim, N. O., Hahn, T., Franke, C., Stiehl, D. P., Wirthner, R., Wenger, R. H., & Katschinski, D. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1877 · Cited by 43
Hypoxia-inducible factor 1 and related gene products in anaesthetic-induced preconditioning
Hieber, S., Huhn, R., Hollmann, M. W., Weber, N. C., & Preckel, B. (2009) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e3283212cbb · Cited by 44
Effect of C-reactive protein on gene expression in vascular endothelial cells
Wang, Q., Zhu, X., Xu, Q., Ding, X., Chen, Y. E., & Song, Q. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00963.2004 · Cited by 49
MA, J., HAN, L. Z., LIANG, H., MI, C., SHI, H., LEE, J. J., & JIN, X. (2014) · Oncology Reports · doi:10.3892/or.2014.3211 · Cited by 43
“All of these activities make the HIF-1 transcription factor an attractive target for the development of new anticancer therapeutics (11-13).”
BackgroundHabanjar, O., Diab‐Assaf, M., Caldefie‐Chezet, F., & Delort, L. (2022) · Biology · doi:10.3390/biology11020339 · Cited by 45
Finosh, G. T., & Jayabalan, M. (2012) · Biomatter · doi:10.4161/biom.19429 · Cited by 46
Cytoprotective effects of fisetin against hypoxia-induced cell death in PC12 cells
Chen, P., Ho, Y.-R., Wu, M., Huang, S., Chen, P., Tai, M., Ho, C., & Yen, J.-H. (2014) · Food & Function · doi:10.1039/c4fo00948g · Cited by 43
Chang, Y., Wu, Q., Tian, T., Li, L., Guo, X., Feng, Z., Zhou, J., Zhang, L., Zhou, S., Feng, G., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3289-2 · Cited by 43
“and mortality [17].”
Lee, N. Y., & Le, Q. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.03.003 · Cited by 50
Huang, C., Lee, C., Chang, K., Chang, W., Liu, Y.-W., Lee, J., & Chen, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3448 · Cited by 44
“Loss of HIF-1α and ARNT also leads to an increased response to radiotherapy, a reduction in tumor growth, and decreased angiogenesis in tumors transplanted into immune-deficient mice [8].”
BackgroundSaijo, H., Tatsumi, N., Arihiro, S., Kato, T., Okabe, M., Tajiri, H., & Hashimoto, H. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.60 · Cited by 42
The histone deacetylase HDAC1 activates HIF1α/VEGFA signal pathway in colorectal cancer
Chen, C., Meng, W., Wang, C., Sun, D., Liu, P., Zhong, X., He, Q., & Yu, W. (2020) · Gene · doi:10.1016/j.gene.2020.144851 · Cited by 51
Luo, Y., Jiang, C., Belanger, A. J., Akita, G. Y., Wadsworth, S. C., Gregory, R. J., & Vincent, K. A. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.017905 · Cited by 44
“This role as a “master switch” has made HIF-1 an attractive candidate for pharmacological manipulation (Giaccia et al., 2003).”
BackgroundBhang, S., Jung, M., Shin, J.-Y., La, W., Hwang, Y. H., Kim, M. J., Kim, B., & Lee, D.-Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.06.018 · Cited by 39
“These results may be attributable to the high expression of HIF-1a that can transactivate genes such as VEGF that possess hypoxia-response elements (HREs) [34].”
BackgroundHypoxia-inducible factor (HIF) inhibitors: a patent survey (2016–2020)
Ban, H. S., Uto, Y., & Nakamura, H. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1874345 · Cited by 44
CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling
Tung, K.-H., Lin, C. W., Kuo, C. C., Li, L.-T., Kuo, Y.-H., Lin, C.-W., & Wu, H. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.12.001 · Cited by 41
“in many types of solid tumors [13–15], and the results from several studies suggest that agents acting directly or indirectly against the expression of HIF-1a have anticancer effects [16,17].”
BackgroundHypoxia‐Inducible Factor 1 Inhibitors
Melillo, G. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35020-9 · Cited by 44
Zimmer, M., Lamb, J., Ebert, B. L., Lynch, M., Neil, C., Schmidt, E., Golub, T. R., & Iliopoulos, O. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2877 · Cited by 40
“It is therefore not surprising that HIF has been proposed, and to a great extent validated, as a therapeutic molecular target for antineoplastic and anti-inflammatory interventions (8).”
Anticancer Mechanisms of Bioactive Compounds from Solanaceae: An Update
Nkwe, D. O., Lotshwao, B., Rantong, G., Matshwele, J. T. P., Kwape, T. E., Masisi, K., Gaobotse, G., Hefferon, K. L., & Makhzoum, A. B. (2021) · Cancers · doi:10.3390/cancers13194989 · Cited by 45
Lipopolysaccharide and Hypoxia‐Induced HIF‐1 Activation in Human Gingival Fibroblasts
Li, J., Li, F. Y. L., Xu, A., Cheng, B., Tsao, S. W., Fung, M., & Leung, W. K. (2011) · Journal of Periodontology · doi:10.1902/jop.2011.110458 · Cited by 43
Clinical significance of hypoxia-inducible factor 1 and VEGF-A in osteosarcoma
Zhao, H., Wu, Y., Yang, C., & Liu, H. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0848-x · Cited by 40
“HIF1 is attracting the interest of pharmacologists and oncologists as a promising drug target [43], because of the frequently reported association of HIF1α overexpression with poor prognosis in clinical studies.”
BackgroundRegulation of Bone Marrow Angiogenesis by Osteoblasts during Bone Development and Homeostasis
Schipani, E., Wu, C., Rankin, E. B., & Giaccia, A. J. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00085 · Cited by 40
Self-citation2′-Epi-uscharin from the Latex of Calotropis gigantea with HIF-1 Inhibitory Activity
Parhira, S., Zhu, G., Jiang, R.-W., Liu, L., Bai, L., & Jiang, Z. (2014) · Scientific Reports · doi:10.1038/srep04748 · Cited by 39
Song, C. W., Kim, H., Cho, H., Kim, M., Paek, S.-H., Park, H. J., Griffin, R. J., Terezakis, S. A., & Cho, L. C. (2022) · Cancers · doi:10.3390/cancers14133273 · Cited by 38
Sato, M., Hirose, K., Kashiwakura, I., AOKI, M., KAWAGUCHI, H., Hatayama, Y., Akimoto, H., Narita, Y., & Takai, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3862 · Cited by 38
“The HIF-1 heterodimer binds to the hypoxia-response element (HRE), thereby activating the expression of numerous hypoxia-response genes, including the pro-angiogenic growth factor vascular endothelial growth factor (VEGF) (13).”
InfluentialWanyin, W., Liwei, D., Lin, J., Hailiang, X., Chang-quan, L., & Li, M. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.12.015 · Cited by 40
“The posttranslational modulation of HIF-1α under hypoxia condition is a very complicated process [44]; further study is needed on the mechanism by which the EEPO affects degradation of HIF-1.”
BackgroundWu, C., Hong, S. S., Cai, X. F., Đạt, N. T., Nan, J., Hwang, B. Y., Lee, J. J., & Lee, D. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.028 · Cited by 38
Wen, Z., Huang, C., Xu, Y., Xiao, Y., Tang, L., Dai, J., Sun, H., Chen, B., & Zhou, M. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.12.020 · Cited by 39
Cancer cell migration and cancer drug screening in oxygen tension gradient chip
Nam, H., Funamoto, K., & Jeon, J. S. (2020) · Biomicrofluidics · doi:10.1063/5.0011216 · Cited by 35
Biju, M. P., Akai, Y., Shrimanker, N., & Haase, V. H. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00233.2005 · Cited by 35
Badawi, Y., & Shi, H. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00239 · Cited by 34
“Regulating HIF-1α induction and the genes induced by HIF-1 under ischemia are highly promising therapeutic targets for cerebral ischemia (Giaccia et al., 2003; Williams et al., 2004; Shi, 2009).”
BackgroundBioengineered smart bacterial carriers for combinational targeted therapy of solid tumours
Alizadeh, S., Esmaeili, A., Barzegari, A., Rafi, M. A., & Omidi, Y. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1737087 · Cited by 34
Shah, T. K., Krishnamachary, B., Wildes, F. B., Mironchik, Y., Kakkad, S. M., Jacob, D., Artemov, D., & Bhujwalla, Z. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4612 · Cited by 37
“CSI, chemical shift imaging; DW, diffusionweighted; ECM, extracellular matrix; ER, estrogen receptor; GLUT, glucose transporter; HIF, hypoxia inducible factor; HK, hexokinase; LDH, lactate dehydrogenase; MMP, matrix metalloproteinase; MR, magnetic resonance; VHL, von Hippel-Lindau; PR, progesterone receptor; qRT-PCR,…”
Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound
Park, K., Lee, H., Lee, S.-H., Lee, D., Lee, T., & Lee, Y.-M. (2016) · OncoTarget · doi:10.18632/oncotarget.13955 · Cited by 25
“For these reasons, HIF-1 could be an important drug target for several diseases such as cancer, stroke, and heart disease, in which hypoxia is a central aspect [12].”
BackgroundFuse, S., Ohuchi, T., Asawa, Y., Sato, S., & Nakamura, H. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.11.009 · Cited by 33
Metadata
- Authors
- Giaccia, A., Siim, B. G., & Johnson, R. S.
- Affiliations
- Stanford Medicine (US)
- University of Auckland (NZ)
- University of California San Diego (US)
- Corresponding author
- Johnson, Randall S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-10-01
- Volume
- 2
- Issue
- 10
- Pages
- 803-811
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2075880922
- Cited by
- 631
- References
- 116
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 10 · 2023: 21 · 2022: 26 · 2021: 19 · 2020: 30 · 2019: 14 · 2018: 26 · 2017: 16 · 2016: 20 · 2015: 20 · 2014: 27 · 2013: 30 · 2012: 29
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-1, hypoxia-inducible factor, hypoxia, therapeutic target, oxygen sensing, transcriptional regulation, cancer, heart disease, stroke, therapeutic targeting
- MeSH terms
- Animals, Cardiovascular Diseases, DNA-Binding Proteins, Gene Expression Regulation, Humans, Neoplasms, Nuclear Proteins, Oxygen, Transcription Factors, Drug Design, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.